PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Therapy Focus: Malaria
From issue 56 of the PharmaDeals Review (2005-02-01)
Malaria is a parasitic disease that affects up to 300 million people and causes over a million fatalities per year. The disease poses a significant threat to the developing world both in terms of health and economics. This feature examines the need for new malaria therapeutics and the importance of non-profit organisations in driving their development.
Available as PDF
(Subscribers only)
Bayer: Seeking Reformulation
From issue 55 of the PharmaDeals Review (2005-01-01)
Bayer's recent agreement with the Dutch biotech Zilip-Pharma to develop a longer acting version of its haemophilia A treatment, Kogenate® (recombinant antihaemophilic factor VIII), makes considerable sense given that novel approaches to tackle the disease are to be found very early on in the development pipeline. This feature considers why the deal is good news for both parties.
Available as PDF
(Subscribers only)
Medarex's Second Recent US$0.5 B Deal
From issue 55 of the PharmaDeals Review (2005-01-01)
Within the space of 2 months Medarex has signed deals with global pharmaceutical giants Pfizer and Bristol-Myers Squibb, each worth in excess of half a billion US dollars. This article considers what makes the New Jersey-based biopharmaceutical company such an impressive deal maker.
Available as PDF
(Subscribers only)
Latin America: A Changing Landscape
From issue 55 of the PharmaDeals Review (2005-01-01)
The Latin American pharma/biotech industry has for some time been faced both with clear opportunities for growth and with various problems. In an attempt to assess how the sector might develop in future, this feature presents a deal-based analysis of Latin American pharma/biotech and examines some of the emergent trends and themes.
Available as PDF
(Subscribers only)
Therapy Focus: Inflammatory Bowel Disease
From issue 55 of the PharmaDeals Review (2005-01-01)
Inflammatory bowel disease (IBD) constitutes a range of conditions, including Crohn's disease and ulcerative colitis. This article looks at therapeutic strategies and developments in the IBD area, focusing on antibody therapies that target α4-integrin or the cytokine TNF, and on other approaches that also involve blocking various cytokines or their receptors, or the NF-κB pathway.
Last Issue PDF
RSS